ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Marinus Pharmaceuticals

< Previous 1 2 3 4 Next >

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

December 30, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

November 12, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

October 24, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

October 17, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

October 15, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

October 09, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 08, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

September 20, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

September 12, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

September 10, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

August 19, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

August 13, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

July 30, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

July 18, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus

June 17, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program

May 17, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 08, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference

May 02, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024

May 01, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

April 15, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

April 05, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

March 27, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 05, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

February 21, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

February 20, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 16, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 04, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update

January 04, 2024

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 07, 2023

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study

November 20, 2023

From Marinus Pharmaceuticals

Via Business Wire

Tickers MRNS

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.